TY - JOUR
T1 - Matrix metalloproteinase-9 as a messenger in the cross talk between obstructive sleep apnea and comorbid systemic hypertension, cardiac remodeling, and ischemic stroke
T2 - A literature review
AU - Mashaqi, Saif
AU - Mansour, Heidi M.
AU - Alameddin, Hanan
AU - Combs, Daniel
AU - Patel, Salma
AU - Estep, Lauren
AU - Parthasarathy, Sairam
N1 - Funding Information:
All authors have seen and approved this manuscript. Work for this study was performed at the University of Arizona College of Medicine, Tucson, AZ. Dr. Mansour reports research grants from the National Institutes of Health (grants NIA R44AG059279, NIAID R21AI135935, NHLBI R01HL137282, NIDA UG3DA047717, NHLBI P01HL103453, NCI P01CA229112, and NIA U01AG066623). Dr. Combs reports current research funding from the National Institutes of Health, the American Heart Association, the Lumind Foundation, and University of Arizona Health Sciences and prior research funding from the American Academy of Sleep Medicine Foundation. Dr. Patel reports research supported by grants from the American Sleep Medicine Foundation (203-JF-18), the National Institutes of Health (HL126140), a University of Arizona Health Sciences Career Development Award, and a Faculty Seed Grant Award. Dr. Parthasarathy reports research grants funded by the National Institutes of Health (HL138377, U01HL128954, IPA-014264-00001, and UG3HL140144), Patient-Centered Outcomes Research Institute (PPRND-1507-31666), the American Sleep Medicine Foundation (ASMF-169-SR-17), and Philips (HRC-1504-RETROPAP-UAZ) and Whoop. Inc. He is a co-investigator on research funded by the National Institutes of Health (MD011600), PCORI (PCS-1504-30430), and the U.S. Department of Defense (W81XWH-14-1-0570). The remaining authors report no conflicts of interest.
Publisher Copyright:
© 2021 American Academy of Sleep Medicine.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Study Objectives: OSA is a common sleep disorder. There is a strong link between sleep-related breathing disorders and cardiovascular and cerebrovascular diseases. Matrix metalloproteinase-9 (MMP-9) is a biological marker for extracellular matrix degradation, which plays a significant role in systemic hypertension, myocardial infarction and postmyocardial infarction heart failure, and ischemic stroke. This article reviews MMP-9 as an inflammatory mediator and a potential messenger between OSA and OSA-induced comorbidities. Methods:We reviewed theMEDLINE database (PubMed) for publications onMMP-9, OSA, and cardiovascular disease, identifying 1,592 studies and including and reviewing 50 articles for this work. Results: There is strong evidence that MMP-9 and tissue inhibitor of metalloproteinase-1 levels are elevated in patients with OSA (mainly MMP-9), systemic hypertension, myocardial infarction, and postmyocardial infarction heart failure. Our study showed variable results that could be related to the sample size or to laboratory methodology. Conclusions: MMP-9 and its endogenous inhibitor, tissue inhibitor of metalloproteinase-1, are a common denominator in OSA, systemic hypertension, myocardial infarction, and heart failure. This characterization makes MMP-9 a target for developing novel selective inhibitors that can serve as adjuvant therapy in patients with OSA, which may ameliorate the cardiovascular and cerebrovascular mortality associated with OSA.
AB - Study Objectives: OSA is a common sleep disorder. There is a strong link between sleep-related breathing disorders and cardiovascular and cerebrovascular diseases. Matrix metalloproteinase-9 (MMP-9) is a biological marker for extracellular matrix degradation, which plays a significant role in systemic hypertension, myocardial infarction and postmyocardial infarction heart failure, and ischemic stroke. This article reviews MMP-9 as an inflammatory mediator and a potential messenger between OSA and OSA-induced comorbidities. Methods:We reviewed theMEDLINE database (PubMed) for publications onMMP-9, OSA, and cardiovascular disease, identifying 1,592 studies and including and reviewing 50 articles for this work. Results: There is strong evidence that MMP-9 and tissue inhibitor of metalloproteinase-1 levels are elevated in patients with OSA (mainly MMP-9), systemic hypertension, myocardial infarction, and postmyocardial infarction heart failure. Our study showed variable results that could be related to the sample size or to laboratory methodology. Conclusions: MMP-9 and its endogenous inhibitor, tissue inhibitor of metalloproteinase-1, are a common denominator in OSA, systemic hypertension, myocardial infarction, and heart failure. This characterization makes MMP-9 a target for developing novel selective inhibitors that can serve as adjuvant therapy in patients with OSA, which may ameliorate the cardiovascular and cerebrovascular mortality associated with OSA.
KW - Hypertension
KW - Ischemic stroke
KW - Matrix metalloproteinase-9
KW - Myocardial infarction
KW - OSA
KW - Remodeling
KW - Tissue inhibitor of metalloproteinase-1
UR - http://www.scopus.com/inward/record.url?scp=85102538325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102538325&partnerID=8YFLogxK
U2 - 10.5664/jcsm.8928
DO - 10.5664/jcsm.8928
M3 - Review article
C2 - 33108267
AN - SCOPUS:85102538325
VL - 17
SP - 567
EP - 591
JO - Journal of Clinical Sleep Medicine
JF - Journal of Clinical Sleep Medicine
SN - 1550-9389
IS - 3
ER -